Key facts
- Chinese pharmaceutical contract manufacturers are experiencing a rally.
- The industry is pushing back against U.S. supply chain pressures.
- Companies are navigating regulatory scrutiny and seeking to maintain global operations.
Chinese pharmaceutical contract manufacturers are experiencing a rally as the industry pushes back against U.S. supply chain pressures. These companies are navigating increased regulatory scrutiny and are working to maintain their global operations. The sector's resilience suggests a strategic response to geopolitical tensions impacting international supply chains.